Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs88 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (392)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | terminated | Phase 1 | 26 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00278395 |
| Vorinostat in Treating Patients With Kidney Cancer |
| completed |
| Phase 2 |
| 14 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Nov 14, 2017 |
| clinicaltrials |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | completed | Phase 1 | 2 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01266837 | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)(MARC-2) | completed | Phase 4 | 64 | iOMEDICO AGINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00401583 | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | completed | Phase 1 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01728948 | Sorafenib in Elderly mRCC | completed | — | 60 | BayerINDUSTRY | 1 | Nov 9, 2017 | clinicaltrials |
| NCT02138578 | Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma | terminated | N/A | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | terminated | Phase 2 | 10 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02809404 | Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)(SPOT) | completed | — | 75 | Radboud University Medical CenterOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT01281488 | Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors | completed | Phase 1 | 28 | City of Hope Medical CenterOTHER | 1 | Oct 13, 2017 | clinicaltrials |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 3 | 339 | Immatics Biotechnologies GmbHINDUSTRY | 11 | Oct 12, 2017 | clinicaltrials |
| NCT00499135 | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2017 | clinicaltrials |
| NCT03161145 | A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread | completed | — | 297 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer(SUNRISES) | terminated | Phase 2 | 41 | Associació per a la Recerca Oncologica, SpainOTHER | 3 | Oct 2, 2017 | clinicaltrials |
| NCT00923845 | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2017 | clinicaltrials |
| NCT02740426 | Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients | unknown | Phase 2 | 200 | Peking University First HospitalOTHER | 1 | Sep 21, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03280459 | Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction(iRARC-KSW) | unknown | — | 200 | Kantonsspital Winterthur KSWOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02236195 | Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes | completed | Phase 2 | 17 | Mirati Therapeutics Inc.INDUSTRY | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01521715 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma(FLIPPER) | completed | Phase 4 | 44 | iOMEDICO AGINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | terminated | Phase 2 | 6 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.OTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT03230201 | Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)(UTUC) | unknown | N/A | 80 | Peking University First HospitalOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT02080650 | Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) | completed | N/A | 62 | Duke UniversityOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01598038 | Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma | terminated | N/A | 41 | Centre Francois BaclesseOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT01687244 | Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | completed | Phase 2 | 40 | FKD Therapies OyINDUSTRY | 0 | Jul 24, 2017 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT00496587 | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01236053 | Cancer in Patients With Gabapentin (GPRD) | completed | — | 2,323,608 | GlaxoSmithKlineINDUSTRY | 0 | Jul 6, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00357760 | Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 2 | Jun 23, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT01803295 | Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC(OPTIMA) | completed | N/A | 80 | UroGen Pharma Ltd.INDUSTRY | 4 | Jun 16, 2017 | clinicaltrials |
| NCT00537056 | Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI | completed | N/A | 17 | Stanford UniversityOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | terminated | N/A | 20 | University of ChicagoOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT01189370 | Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT02150369 | Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms | completed | — | 32 | Duke UniversityOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT03033186 | Everolimus TDM to Predict Long Term Toxicity(Foresight) | unknown | — | 40 | Maastricht University Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT01138124 | Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) | completed | — | 54,202 | GlaxoSmithKlineINDUSTRY | 0 | May 30, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Nov 17, 2017source: clinicaltrials